Induction of experimental obstructive cholestasis in mice

Laboratory Animals

Volumn 49, Issue , 2015, Pages 70-80

  Tag, Cg ^a   Weiskirchen, s ^a   Hittatiya, k ^b   Tacke, f ^a   Tolba, rh ^c   Weiskirchen, R ^a  

^a UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^b UNIVERSITY HOSPITAL BONN   (Germany)

^c RWTH AACHEN UNIVERSITY   (Germany)

Author keywords

biliary obstruction; cell infiltration; cirrhosis; fibrosis; jaundice

Indexed keywords

ANIMAL; BILE DUCT; CHOLESTASIS; DISEASE MODEL; HUMAN; LABORATORY; LIGATION; MOUSE; PATHOLOGY; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; STANDARDS;

ANIMALS; BILE DUCTS; CHOLESTASIS; DISEASE MODELS, ANIMAL; GUIDELINES AS TOPIC; HUMANS; LABORATORY ANIMAL SCIENCE; LIGATION; MICE;

EID: 84940984171     PISSN: 00236772     EISSN: 17581117     Source Type: Journal    
DOI: 10.1177/0023677214567748     Document Type: Article

References (53)

1. Mayer H. Über Veränderungen des Leberparenchyms bei dauerndem Verschluss des Ductus choledochus. Med Jahrb 1872; 1: 133–142.
2. Cameron GR Oakley CL. Ligation of the common bile duct. J Pathol 1932; 35: 769–798.
3. Ogata T. Beiträge zur experimentell erzeugten Lebercirrhose und zur Pathogenese des mit spezieller Berücksichtigung der Gallenkapillaren bei der Unterbindung des Ductus choledochus und der Ikterogenvergiftung. Beitr z Pathol Anat z Allg Pathol 1913; 55: 236–314.
4. McMaster PD. Do species lacking a gall bladder possess its functional equivalent? J Exp Med 1922; 35: 127–140.
5. Cameron GR Hasan SM. Disturbances of structure and function in the liver as the result of biliary obstruction. J Pathol 1958; 75: 333–349.
6. Kountouras J Billing BH Scheuer PJ. Prolonged bile duct obstruction: a new experimental model for cirrhosis in the rat. Br J Exp Pathol 1984; 65: 305–311.
7. Heinrich S Georgiev P Weber A Vergopoulos A Graf R Clavien PA. Partial bile duct ligation in mice: a novel model of acute cholestasis. Surgery 2011; 149: 445–451.
8. Arias M Sauer-Lehnen S Treptau J. Adenoviral expression of a transforming growth factor-beta1 antisense mRNA is effective in preventing liver fibrosis in bile-duct ligated rats. BMC Gastroenterol 2003; 3: 29–29.
9. Borkham-Kamphorst E Herrmann J Stoll D Treptau J Gressner AM Weiskirchen R. Dominant-negative soluble PDGF-beta receptor inhibits hepatic stellate cell activation and attenuates liver fibrosis. Lab Invest 2004; 84: 766–777.
10. Meurer SK Tihaa L Borkham-Kamphorst E Weiskirchen R. Expression and functional analysis of endoglin in isolated liver cells and its involvement in fibrogenic Smad signalling. Cell Signal 2011; 23: 683–699.
11. Borkham-Kamphorst E Drews F Weiskirchen R. Induction of lipocalin-2 expression in acute and chronic experimental liver injury moderated by pro-inflammatory cytokines interleukin-1β through nuclear factor-κB activation. Liver Int 2011; 31: 656–665.
12. Borkham-Kamphorst E van Roeyen CR Van de Leur E Floege J Weiskirchen R. CCN3/NOV small interfering RNA enhances fibrogenic gene expression in primary hepatic stellate cells and cirrhotic fat storing cell line CFSC. J Cell Commun Signal 2012; 6: 11–25.
13. Borkham-Kamphorst E Huss S Van de Leur E Haas U Weiskirchen R. Adenoviral CCN3/NOV gene transfer fails to mitigate liver fibrosis in an experimental bile duct ligation model because of hepatocyte apoptosis. Liver Int 2012; 32: 1342–1353.
14. Borkham-Kamphorst E Zimmermann HW Gassler N. Factor VII activating protease (FSAP) exerts anti-inflammatory and anti-fibrotic effects in liver fibrosis in mice and men. J Hepatol 2013; 58: 104–111.
15. Martin IV Borkham-Kamphorst E Zok S. Platelet-derived growth factor (PDGF)-C neutralization reveals differential roles of PDGF receptors in liver and kidney fibrosis. Am J Pathol 2013; 182: 107–117.
16. Borkham-Kamphorst E van de Leur E Zimmermann HW. Protective effects of lipocalin-2 (LCN2) in acute liver injury suggest a novel function in liver homeostasis. Biochim Biophys Acta 2013; 1832: 660–673.
17. Borkham-Kamphorst E Schaffrath C Van de Leur E. The anti-fibrotic effects of CCN1/CYR61 in primary portal myofibroblasts are mediated through induction of reactive oxygen species resulting in cellular senescence, apoptosis and attenuated TGF-β signaling. Biochim Biophys Acta 2014; 1843: 902–914.
18. Karlmark KR Zimmermann HW Roderburg C. The fractalkine receptor CX3CR1 protects against liver fibrosis by controlling differentiation and survival of infiltrating hepatic monocytes. Hepatology 2010; 52: 1769–1782.
19. Heymann F Hammerich L Storch D. Hepatic macrophage migration and differentiation critical for liver fibrosis is mediated by the chemokine receptor C-C motif chemokine receptor 8 in mice. Hepatology 2012; 55: 898–909.
20. Ehling J Bartneck M Wei X. CCL2-dependent infiltrating macrophages promote angiogenesis in progressive liver fibrosis. Gut 2014; 63: 1960–1971.
21. Aller MA Arias JL García-Domínguez J Arias JI Durán M Arias J. Experimental obstructive cholestasis: the wound-like inflammatory liver response. Fibrogenesis Tissue Repair 2008; 1: 6–6.
22. Aller MA Arias JL Prieto I Losada M Arias J. Bile duct ligation: step-by-step to cholangiocyte inflammatory tumorigenesis. Eur J Gastroenterol Hepatol 2010; 22: 651–661.
23. Aller MA Arias N Prieto I. A half century (1961–2011) of applying microsurgery to experimental liver research. World J Hepatol 2012; 4: 199–208.
24. Gressner AM Weiskirchen R. Modern pathogenetic concepts of liver fibrosis suggest stellate cells and TGF-β as major players and therapeutic targets. J Cell Mol Med 2006; 10: 76–99.
25. Rodríguez-Garay EA. Cholestasis: human disease and experimental animal models. Ann Hepatol 2003; 2: 150–158.
26. Hayashi H Sakai T. Animal models for the study of liver fibrosis: new insights from knockout mouse models. Am J Physiol Gastrointest Liver Physiol 2011; 300: G729–G738.
27. Rosenberg P Sjöström M Söderberg C Kinnman N Stål P Hultcrantz R. Attenuated liver fibrosis after bile duct ligation and defective hepatic stellate cell activation in neural cell adhesion molecule knockout mice. Liver Int 2011; 31: 630–641.
28. Uppal H Saini SP Moschetta A. Activation of LXRs prevents bile acid toxicity and cholestasis in female mice. Hepatology 2007; 45: 422–432.
29. Zimmermann H Blaser H Zimmermann A Reichen J. Effect of development on the functional and histological changes induced by bile-duct ligation in the rat. J Hepatol 1994; 20: 231–239.
30. Zhang Y Hong JY Rockwell CE Copple BL Jaeschke H Klaassen CD. Effect of bile duct ligation on bile acid composition in mouse serum and liver. Liver Int 2012; 32: 58–69.
31. Seki E De Minicis S Osterreicher CH. TLR4 enhances TGF-β signaling and hepatic fibrosis. Nat Med 2007; 13: 1324–1332.
32. Seki E De Minicis S Gwak GY. CCR1 and CCR5 promote hepatic fibrosis in mice. J Clin Invest 2009; 119: 1858–1870.
33. Tarcin O Basaranoglu M Tahan V. Time course of collagen peak in bile duct-ligated rats. BMC Gastroenterol 2011; 11: 45–45.
34. Georgiev P Jochum W Heinrich S. Characterization of time-related changes after experimental bile duct ligation. Br J Surg 2008; 95: 646–656.
35. Giebeler A Boekschoten MV Klein C. c-Met confers protection against chronic liver tissue damage and fibrosis progression after bile duct ligation in mice. Gastroenterology 2009; 137: 297–308, 308.e1–4.
36. Sigal M Siebert N Zechner D. Darbepoetin-α inhibits the perpetuation of necro-inflammation and delays the progression of cholestatic fibrosis in mice. Lab Invest 2010; 90: 1447–1456.
37. Huss S Schmitz J Goltz D Fischer HP Büttner R Weiskirchen R. Development and evaluation of an open source Delphi-based software for morphometricquantification of liver fibrosis. Fibrogenesis Tissue Repair 2010; 3: 10–10.
38. Iredale JP Benyon RC Pickering J. Mechanisms of spontaneous resolution of rat liver fibrosis. Hepatic stellate cell apoptosis and reduced hepatic expression of metalloproteinase inhibitors. J Clin Invest 1998; 102: 538–549.
39. Issa R Williams E Trim N. Apoptosis of hepatic stellate cells: involvement in resolution of biliary fibrosis and regulation by soluble growth factors. Gut 2001; 48: 548–557.
40. Popov Y Sverdlov DY Bhaskar KR. Macrophage-mediated phagocytosis of apoptotic cholangiocytes contributes to reversal of experimental biliary fibrosis. Am J Physiol Gastrointest Liver Physiol 2010; 298: G323–G334.
41. Yang L Kwon J Popov Y. Vascular endothelial growth factor promotes fibrosis resolution and repair in mice. Gastroenterology 2014; 146: 1339–1350.e1.
42. Balcombe JP Barnard ND Sandusky C. Laboratory routines cause animal stress. Contemp Top Lab Anim Sci 2004; 43: 42–51.
43. Schimpl G Pesendorfer P Steinwender G Feierl G Ratschek M Höllwarth ME. Bacterial translocation in chronic portal hypertensive and common bile duct-ligated growing rats. Pediatr Surg Int 1996; 11: 322–325.
44. Skelly DT Hennessy E Dansereau MA Cunningham C. A systematic analysis of the peripheral and CNS effects of systemic LPS, IL-1Β, TNF-α and IL-6 challenges in C57BL/6 mice. PLoS One 2013; 8: e69123–e69123.
45. Alaish SM Torres M Ferlito M Sun CC De Maio A. The severity of cholestatic injury is modulated by the genetic background. Shock 2005; 24: 412–416.
46. Alaish SM Smith AD Timmons J. Gut microbiota, tight junction protein expression, intestinal resistance, bacterial translocation and mortality following cholestasis depend on the genetic background of the host. Gut Microbes 2013; 4: 292–305.
47. Jonassen TE Christensen S Sørensen AM. Effects of chronic octreotide treatment on renal changes during cirrhosis in rats. Hepatology 1999; 29: 1387–1395.
48. Marley R Holt S Fernando B. Lipoic acid prevents development of the hyperdynamic circulation in anesthetized rats with biliary cirrhosis. Hepatology 1999; 29: 1358–1363.
49. Martínez-Prieto C Ortíz MC Fortepiani LA Ruiz-Maciá J Atucha NM García-Estañ J. Haemodynamic and renal evolution of the bile duct-ligated rat. Clin Sci (Lond) 2000; 98: 611–617.
50. Ortiz MC Manriquez MC Nath KA Lager DJ Romero JC Juncos LA. Vitamin E prevents renal dysfunction induced by experimental chronic bile duct ligation. Kidney Int 2003; 64: 950–961.
51. Iida A Yoshidome H Shida T. Does prolonged biliary obstructive jaundice sensitize the liver to endotoxemia? Shock 2009; 31: 397–403.
52. Wuestefeld T Klein C Streetz KL. Lack of gp130 expression results in more bacterial infection and higher mortality during chronic cholestasis in mice. Hepatology 2005; 42: 1082–1090.
53. Morton DB. A systematic approach for establishing humane endpoints. ILAR J 2000; 41: 80–86.